TP53 and thyroid cancer: Our discoveries about functional enrichment analysis are in accordance with those of Landa et al. Landa et al demonstrated that compared to poorly differentiated thyroid cancer (PDTC), a greater mutation burden existed in ATCs, with TERT promoter's mutations' greater frequency, TP53, PI3K/AKT/mTOR pathway effectors, histone methyltransferases, and SWI/SNF subunits being included [32].